170 related articles for article (PubMed ID: 38387193)
1. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy.
Chen M; Wang S
Int Immunopharmacol; 2024 Mar; 130():111717. PubMed ID: 38387193
[TBL] [Abstract][Full Text] [Related]
2. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
[TBL] [Abstract][Full Text] [Related]
4. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
Mimura K; Teh JL; Okayama H; Shiraishi K; Kua LF; Koh V; Smoot DT; Ashktorab H; Oike T; Suzuki Y; Fazreen Z; Asuncion BR; Shabbir A; Yong WP; So J; Soong R; Kono K
Cancer Sci; 2018 Jan; 109(1):43-53. PubMed ID: 29034543
[TBL] [Abstract][Full Text] [Related]
6. MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
Li L; Zhang Y; Hu W; Zou F; Ning J; Rao T; Ruan Y; Yu W; Cheng F
J Cell Mol Med; 2023 Oct; 27(19):2922-2936. PubMed ID: 37480214
[TBL] [Abstract][Full Text] [Related]
7. SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway.
Gu W; Qi G; Chen L
Iran J Immunol; 2023 Sep; 20(3):335-347. PubMed ID: 37452634
[TBL] [Abstract][Full Text] [Related]
8. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of PD-L1 in Senescence and Aging.
Onorati A; Havas AP; Lin B; Rajagopal J; Sen P; Adams PD; Dou Z
Mol Cell Biol; 2022 Oct; 42(10):e0017122. PubMed ID: 36154662
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the expression of PD-L1 and
Li J; Chen R; Chen Y; Xia Q; Zhou X; Xia Q; Wang C; Wan L; Bao H; Huang G; Liu J
Br J Cancer; 2023 Aug; 129(3):541-550. PubMed ID: 37311977
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
12. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Xu Y; Song G; Xie S; Jiang W; Chen X; Chu M; Hu X; Wang ZW
Mol Ther; 2021 Jun; 29(6):1958-1969. PubMed ID: 33932597
[TBL] [Abstract][Full Text] [Related]
13. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
Alburquerque-Bejar JJ; Navajas-Chocarro P; Saigi M; Ferrero-Andres A; Morillas JM; Vilarrubi A; Gomez A; Mate JL; Munoz-Marmol AM; Romero OA; Blecua P; Davalos V; Esteller M; Pros E; Llabata P; Torres-Diz M; Esteve-Codina A; Sanchez-Cespedes M
Cell Rep Med; 2023 Apr; 4(4):101006. PubMed ID: 37044092
[TBL] [Abstract][Full Text] [Related]
14. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
16. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
18. The association between PI3K, JAK/STAT pathways with the PDL-1 expression in prostate cancer.
Kazan O; Kir G; Culpan M; Cecikoglu GE; Atis G; Yildirim A
Andrologia; 2022 Nov; 54(10):e14541. PubMed ID: 35880672
[TBL] [Abstract][Full Text] [Related]
19. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
20. Targeting the programmed death-1 pathway in lymphoid neoplasms.
Ok CY; Young KH
Cancer Treat Rev; 2017 Mar; 54():99-109. PubMed ID: 28242522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
